You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for TESTOSTERONE CYPIONATE


✉ Email this page to a colleague

« Back to Dashboard


TESTOSTERONE CYPIONATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Am Regent TESTOSTERONE CYPIONATE testosterone cypionate INJECTABLE;INJECTION 207742 ANDA American Regent, Inc. 0517-1830-01 1 VIAL in 1 BOX (0517-1830-01) / 1 mL in 1 VIAL 2019-07-19
Am Regent TESTOSTERONE CYPIONATE testosterone cypionate INJECTABLE;INJECTION 207742 ANDA Alvogen Inc. 47781-910-91 10 VIAL, MULTI-DOSE in 1 CARTON (47781-910-91) / 10 mL in 1 VIAL, MULTI-DOSE (47781-910-22) 2022-11-02
Am Regent TESTOSTERONE CYPIONATE testosterone cypionate INJECTABLE;INJECTION 207742 ANDA Alvogen Inc. 47781-911-93 1 VIAL, SINGLE-DOSE in 1 CARTON (47781-911-93) / 1 mL in 1 VIAL, SINGLE-DOSE 2022-11-02
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: Testosterone Cyponate

Last updated: January 8, 2026

Summary

Testosterone Cyponate, also known as Testosterone Cypionate, is a synthetic derivative of testosterone used primarily in hormone replacement therapy and testosterone deficiency management. Recognized for its long-acting profile, it is administered via intramuscular injection, with typical therapy protocols requiring sustained plasma testosterone levels. The global market for Testosterone Cypionate is driven by increasing demand for hormonal therapies, growth in aging populations, and advancements in manufacturing quality standards.

This article provides a comprehensive analysis of key suppliers, industry market dynamics, regulatory considerations, and procurement strategies, serving as a definitive resource for healthcare providers, pharmaceutical companies, and investors.


What Are the Major Suppliers of Testosterone Cypionate?

Numerous pharmaceutical manufacturers supply Testosterone Cypionate globally, encompassing brand-name formulations, generic versions, and active pharmaceutical ingredients (APIs). The supply chain is complex, involving API producers, finished drug manufacturers, and distributors.

Leading API Producers

Company Country Operational Highlights Certifications & Quality Standards Estimated Production Capacity (kg/year)
Watson Pharmaceuticals (Actavis) USA Major API producer, with extensive steroid manufacturing GMP, ISO 9001 500+ kg
Hisun Pharmaceutical China Produces bulk testosterone esters, including Testosterone Cypionate GMP, ISO 9001 1,000+ kg
Cipla Limited India API manufacturing with a broad steroid portfolio WHO-GMP, ISO 9001 300+ kg
BG Chemicals (Balkan Pharmaceuticals) Bulgaria Specializes in hormonal APIs GMP, CEP 150 kg
Synthetics & Reagents Inc. India Focused on pharmaceutical intermediates and APIs GMP 200 kg

Top Finished Product Manufacturers

Company Country Brands & Product Names Market Focus Production Volume (Units/Year)
AbbVie (formerly Abbott) USA Depo-Testosterone U.S. and Global Millions of vials annually
Mylan / Pfizer USA Testosterone Cypionate (generic) Global Significant market share in generics
Gefton India Testostrogen-C Asian markets Large-scale manufacturing
Hua Pharmaceuticals China Testosterone Cypionate Asian & Middle Eastern markets Growing distribution
Bhupal Pharma India Testosterone Cypionate USP Local and regional markets Focused on Brazil, Africa

Where Are the Key Markets for Testosterone Cypionate Supplies?

Global Distribution Breakdown

Region Major Markets Regulatory Status Demand Drivers Leading Suppliers
North America USA, Canada FDA (US), Health Canada Aging population, Testosterone replacement therapy (TRT) Abbott, Mylan, Watson
Europe Germany, UK, Bulgaria EMA, MHRA, Bulgarian Food Safety Agency TRT, Hormonal deficiencies Balkan Pharmaceuticals, GSK
Asia-Pacific China, India, Australia CFDA, CDSCO Expanding pharmaceutical manufacturing Hisun, Cipla, GSK
Latin America Brazil, Mexico ANVISA Increasing TRT prescriptions Bhupal Pharma, local compounding pharmacies
Middle East & Africa UAE, South Africa Local regulatory agencies Growing demand for hormone therapy Hua Pharmaceuticals

Supply Chain Dynamics and Procurement Strategies

API Supply Chain Flow

  1. Raw Material Sourcing: Testosterone base raw materials sourced from petrochemical or plant-based sources.
  2. API Synthesis: Chemical synthesis in controlled GMP facilities ensuring purity and potency.
  3. Quality Testing: Rigorous QC to meet pharmacopeial standards, including USP or BP specifications.
  4. Export & Distribution: APIs shipped globally, often through licensed distributors adhering to international pharmaceutical transport regulations.

Procurement Considerations

Factor Details Implication
Regulatory Compliance Ensure suppliers meet local & international standards Essential for legal import & use
Certifications GMP, ISO, CEP, DMF availability Guarantees quality and safety
Pricing & Capacity Bulk discounts on large orders; capacity constraints Budget management & supply assurance
Lead Times Vary from 4 to 12 weeks Planning ahead for production schedules
Market Supply Security Diversify suppliers, monitor geopolitical risks Prevent shortages or delays

Comparison of Leading API Suppliers

Parameter Watson Pharmaceuticals Hisun Pharmaceutical Cipla BG Chemicals Synthetics & Reagents Inc.
Country USA China India Bulgaria India
Certifications GMP, ISO 9001 GMP, ISO 9001 WHO-GMP GMP, CEP GMP
Production Capacity (kg/year) >500 >1,000 ~300 ~150 ~200
Price Range (per kg) $10,000 - $15,000 $8,500 - $12,000 $9,000 - $13,000 $9,500 - $13,000 $9,200 - $12,500
Lead Time 4-8 weeks 4-6 weeks 6-8 weeks 4-7 weeks 5-8 weeks

Summary of Regulatory and Quality Standards

Standard/Regulation Description Applicability Relevance
USP United States Pharmacopeia standards US market Ensures API purity and potency
EP European Pharmacopoeia EU market Regulatory compliance across European countries
WHO-GMP World Health Organization Good Manufacturing Practices Global Necessary for export licensing
CEP (Certificate of Suitability) Certification for active substances EU market Market access facilitation
DMF (Drug Master File) Submission of detailed manufacturing info US, EU Regulatory approval process

Key Market Trends & Future Outlook

Market Drivers

  • Growing demand for testosterone replacement therapy (TRT). The global TRT market is projected to reach USD 2.5 billion by 2027, growing at a CAGR of 6.8% [1].
  • Increasing aging populations worldwide. Particularly in North America, Europe, and parts of Asia.
  • Shift towards generic testosterone formulations driven by patent expirations of branded products.

Supply Challenges

  • Raw material fluctuations impacting API pricing.
  • Stringent regulatory policies restricting imports and exports.
  • Geo-political tensions affecting manufacturing and distribution.

Opportunities

  • Emerging markets in Africa and Southeast Asia show increasing healthcare infrastructure and demand.
  • Development of biosimilar testosterone products for cost-effective therapies.
  • Technological advancements in API synthesis enhancing purity and reducing costs.

FAQs

1. What are the main differences between Testosterone Cypionate and other testosterone esters?

Testosterone Cypionate offers a long half-life (~8 days), requiring injections every 1-2 weeks. Compared to testosterone enanthate (~4-5 days half-life) or propionate (~2 days), it provides more stable blood levels, reducing injection frequency. The choice depends on patient tolerance, medical protocols, and pharmacokinetic preferences.

2. How can healthcare providers ensure the quality of Testosterone Cypionate from suppliers?

Providers should verify certifications such as GMP, ISO, and EMA approval, review Certificates of Analysis (CoA), and establish relationships with trusted, audited suppliers. Additionally, consider sourcing from suppliers with validated manufacturing facilities and regulatory approvals.

3. What are the risks associated with sourcing from unapproved or rogue suppliers?

Risks include counterfeit products, contaminated APIs, inconsistent potency, and regulatory penalties. Such risks compromise patient safety, lead to legal liabilities, and damage reputations.

4. Are there regional restrictions on the import/export of Testosterone Cypionate?

Yes. Many countries require import permits, licensing, and adherence to international trade laws. For example, the US DEA categorizes testosterone as a Schedule III substance, necessitating strict handling and documentation.

5. What is the typical lead time for acquiring Testosterone Cypionate APIs?

Lead times vary from 4 to 8 weeks, depending on the supplier, regulatory clearance, and logistics. Advanced planning and long-term contracts can mitigate delays.


Key Takeaways

  • Global Suppliers: The testosterone cypionate API market features key producers primarily in the US, China, India, and Bulgaria, with a robust network serving both generic and branded finished drug manufacturers.
  • Quality & Regulation: Suppliers with GMP, ISO certifications, and compliance with pharmacopeial standards are critical to ensuring product safety and efficacy.
  • Market Dynamics: Increasing demand driven by aging populations and TRT growth presents opportunities, yet supply chain vulnerabilities and regulatory complexities require strategic sourcing.
  • Procurement Strategy: Diversification, due diligence, and adherence to regulatory standards are essential for maintaining supply chain integrity.
  • Future Trends: Market expansion in emerging regions, technological advances, and biosimilar development will influence supply and pricing dynamics.

References

[1] Grand View Research, "Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report", 2022.

[2] GlobalData, "Pharmaceuticals & Healthcare - Steroids Market Analysis", 2023.

[3] U.S. Food & Drug Administration (FDA), Regulatory Guidelines for Testosterone Products, 2022.

[4] European Medicines Agency (EMA), Active Substance Master File (ASMF) guidance, 2021.

[5] WHO, Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients, 2022.


Note: This detailed analysis is intended to assist healthcare providers, pharmaceutical companies, and investors in making informed procurement and strategic decisions regarding Testosterone Cypionate supply chains.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.